Douglas C M, Marrinan J A, Li W, Kurtz M B
Merck Research Laboratories, Rahway, New Jersey 07065.
J Bacteriol. 1994 Sep;176(18):5686-96. doi: 10.1128/jb.176.18.5686-5696.1994.
A novel, potent, semisynthetic pneumocandin, L-733,560, was used to isolate a resistant mutant in Saccharomyces cerevisiae. This compound, like other pneumocandins and echinocandins, inhibits 1,3-beta-D-glucan synthase from Candida albicans (F.A. Bouffard, R.A. Zambias, J. F. Dropinski, J.M. Balkovec, M.L. Hammond, G.K. Abruzzo, K.F. Bartizal, J.A. Marrinan, M. B. Kurtz, D.C. McFadden, K.H. Nollstadt, M.A. Powles, and D.M. Schmatz, J. Med. Chem. 37:222-225, 1994). Glucan synthesis catalyzed by a crude membrane fraction prepared from the S. cerevisiae mutant R560-1C was resistant to inhibition by L-733,560. The nearly 50-fold increase in the 50% inhibitory concentration against glucan synthase was commensurate with the increase in whole-cell resistance. R560-1C was cross-resistant to other inhibitors of C. albicans 1,3-beta-D-glucan synthase (aculeacin A, dihydropapulacandin, and others) but not to compounds with different modes of action. Genetic analysis revealed that enzyme and whole-cell pneumocandin resistance was due to a single mutant gene, designated etg1-1 (echinocandin target gene 1), which was semidominant in heterozygous diploids. The etg1-1 mutation did not confer enhanced ability to metabolize L-733,560 and had no effect on the membrane-bound enzymes chitin synthase I and squalene synthase. Alkali-soluble beta-glucan synthesized by crude microsomes from R560-1C was indistinguishable from the wild-type product. 1,3-beta-D-Glucan synthase activity from R560-1C was fractionated with NaCl and Tergitol NP-40; reconstitution with fractions from wild-type membranes revealed that drug resistance is associated with the insoluble membrane fraction. We propose that the etg1-1 mutant gene encodes a subunit of the 1,3-beta-D-glucan synthase complex.
一种新型强效半合成的肺念珠菌素L-733,560被用于分离酿酒酵母中的抗性突变体。该化合物与其他肺念珠菌素和棘白菌素一样,可抑制白色念珠菌的1,3-β-D-葡聚糖合酶(F.A.布法德、R.A.赞比亚斯、J.F.德罗平斯基、J.M.巴尔科韦茨、M.L.哈蒙德、G.K.阿布鲁佐、K.F.巴蒂扎尔、J.A.马林南、M.B.库尔茨、D.C.麦克法登、K.H.诺尔斯塔特、M.A.鲍尔斯和D.M.施马茨,《药物化学杂志》37:222 - 225, 1994)。由酿酒酵母突变体R560 - 1C制备的粗膜部分催化的葡聚糖合成对L-733,560的抑制具有抗性。对葡聚糖合酶的50%抑制浓度增加近50倍与全细胞抗性的增加相当。R560 - 1C对白色念珠菌1,3-β-D-葡聚糖合酶的其他抑制剂(刺囊霉素A、二氢棒曲霉素等)具有交叉抗性,但对具有不同作用方式的化合物不具有交叉抗性。遗传分析表明,酶和全细胞对肺念珠菌素的抗性归因于一个单一的突变基因,命名为etg1 - 1(棘白菌素靶基因1),它在杂合二倍体中是半显性的。etg1 - 1突变并未赋予代谢L-733,560的能力增强,并且对膜结合酶几丁质合酶I和角鲨烯合酶没有影响。由R560 - 1C的粗微粒体合成的碱溶性β-葡聚糖与野生型产物没有区别。来自R560 - 1C的1,3-β-D-葡聚糖合酶活性用氯化钠和壬基酚聚氧乙烯醚-40进行分级分离;用野生型膜的组分进行重组表明,耐药性与不溶性膜组分有关。我们推测etg1 - 1突变基因编码1,3-β-D-葡聚糖合酶复合物的一个亚基。